Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
- Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
- Indication
Teriparatide is indicated:
- Associated Conditions
- Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis
- Associated Therapies
- -
Once Weekly Parathyroid Hormone for Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2003-07-30
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 50
- Registration Number
- NCT00065637
- Locations
- 🇺🇸
St Joseph Hospital, Bangor, Maine, United States
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2003-01-14
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 428
- Registration Number
- NCT00051558
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ponce, Puerto Rico
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
- Conditions
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00046137
- Locations
- 🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician"., Dallas, Texas, United States
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 330
- Registration Number
- NCT00035256
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sainte -Foy, Quebec, Canada
Combination Osteogenic Therapy in Established Osteoporosis
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018447
- Locations
- 🇺🇸
Jerry L. Pettis Memorial Veterans Medical Center, Loma Linda, California, United States
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2000-03-27
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Helen Hayes Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT00005006
- Locations
- 🇺🇸
Helen Hayes Hospital, Clinical Research Center, West Haverstraw, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.